MyoVista hsECG testing device has been developed for front-line screening of cardiac disease in both symptomatic and asymptomatic patients.
A press conference for the launch of the Ddu Credit Verification service was successfully held at Shenzhenair International Hotel, HallⅠin Shenzhen, China on August 18, 2017.
NeoSync has announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13m.
Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
The 27th Florida International Medical Exhibition (FIME) was grandly held in Orlando, USA from August 8th to August 10th, 2017. As the leading global pharmaceutical and medical device B2B online platform, Ddu, attended the exhibition along with products of high priority members, becoming one of the most popular brands at FIME.
New treatments for neurodegenerative disease and motion disability will be developed by a research collaboration between digital healthcare solutions provider MC10 and US-based rehabilitation research hospital, Shirley Ryan AbilityLab.
Vascular focused device developer VentureMed said today it raised $15 million in a Series B round.
In support of the project in adopting Atlas Genetic's io rapid diagnostic platform into UK sexual health clinics, Innovative UK has awarded them a grant of £2 million.
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Transchiatal esophagectomy procedures utilizing robotic platforms are “effective and safe” for carefully selected patients, according to a new study from Allina Health hospitals.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.